Boardroom Alpha
Start trial
Boardroom Alpha
CNMD · Additional Proxy Materials (DEFA14A) · Filed April 7, 2026

Conmed Corp — Additional Proxy Materials (DEFA14A)

Form
DEFA14A
Filed
April 7, 2026
Ticker
CNMD
Accession
0001140361-26-013497
Conmed Corp on Boardroom AlphaView on SEC EDGAR
Boardroom Alpha · Filing insights

ConMed's 2026 proxy: elect seven directors, approve executive compensation, and ratify PwC; board urges voting For all.

About Conmed Corp
Market cap
$1.0B
1Y TSR
−33.6%
3Y TSR
−34.4%
Board grade
C-
Sector
Healthcare
CEO
Pat Beyer
Last annual meeting: May 18, 2026 · View full Conmed Corp profile →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

 

Filed by the Registrant ☑

Filed by a Party other than the Registrant ☐


Check the appropriate box:

 

☐

Preliminary Proxy Statement

 

☐

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

 

☐

Definitive Proxy Statement

 

☒

Definitive Additional Materials

 

☐

Soliciting Material Pursuant to §240.14a-12

CONMED CORPORATION

(Name of Registrant as Specified In Its Charter)

Payment of Filing Fee (Check the appropriate box):

 

☑

No fee required.

 

☐

Fee paid previously with preliminary materials.

 

☐

Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


Your Vote Counts!  CONMED CORPORATION  ATTN: CORPORATE SECRETARY, LEGAL DEPARTMENT 11311 CONCEPT BLVD  LARGO, FL 33773  You invested in CONMED CORPORATION and it’s time to vote!  You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the  availability of proxy materials for the stockholder meeting to be held on May 18, 2026.  Get informed before you vote  View the Proxy Statement, the Notice of Annual Meeting and the 2025 Annual Report online OR you can receive a free paper  or email copy of the material(s) by requesting prior to May 4, 2026. If you would like to request a copy of the material(s) for the Annual Meeting and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.  Vote Virtually at the Meeting*  May 18, 2026  11:30 AM EDT  Virtually at: www.virtualshareholdermeeting.com/CNMD2026  CONMED CORPORATION  2026 Annual Meeting  Vote by May 17, 2026 11:59 PM ET. For shares held in a Plan, vote by May 13, 2026 11:59 PM ET.  *Please check the meeting materials for any special requirements for meeting attendance.  Smartphone users  Point your camera here and vote without entering a control number  For complete information and to vote, visit www.ProxyVote.com  Control #  V85688-P42296

 Vote at www.ProxyVote.com  THIS IS NOT A VOTABLE BALLOT  This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters.  Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.  1. Election of seven directors to serve on the Company’s Board of Directors.  For All  Nominees:  Patrick J. Beyer 05) Mark Kaye  David Bronson 06) Kim Kelderman  LaVerne H. Council 07) Barbara J. Schwarzentraub  Charles M. Farkas  2. Advisory vote to approve named executive officer compensation.  For  3. Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.  For  NOTE: Such other business as may properly come before the meeting and any adjournment or postponement thereof.  Voting Items  Board Recommends  V85689-P42296 

From this filing to the vote

Forecast every director vote the day the proxy files.

Meeting Forecast scores each director up for re-election + every contested situation, rebuilt daily across 6,000+ U.S. public companies. The same model that called the LULU contested proxy lives on every meeting you see here.

See Meeting ForecastSchedule a Demo

Independent — issuer-pays-free, ideology-free, U.S.-owned.

More filings

Other filings from Conmed Corp (CNMD)

Continue researching
Reference

Frequently asked questions

When did Conmed Corp file this DEFA14A?
Conmed Corp (CNMD) filed this Additional Proxy Materials (DEFA14A) with the SEC on April 7, 2026. The accession number assigned by EDGAR is 0001140361-26-013497.
What does a DEFA14A disclose?
DEFA14A is additional definitive proxy soliciting material filed in connection with a shareholder meeting — supplemental letters, slides, or amendments issued after the main proxy statement.
What is the key takeaway from this filing?
ConMed's 2026 proxy: elect seven directors, approve executive compensation, and ratify PwC; board urges voting For all. This is Boardroom Alpha's one-line summary of the additional proxy materials; see the full filing text above for the formal disclosure.
Where can I find Conmed Corp's prior proxy statements on EDGAR?
The SEC EDGAR browser lists every DEFA14A Conmed Corp has filed under CIK 816956, sortable by date. Use the "View on SEC EDGAR" link in the page header, or browse directly via https://www.sec.gov/cgi-bin/browse-edgar.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer